Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

1. Wu, Y.-L.
2. Cheng, Y.
3. Zhou, J.
4. Lu, S.
5. Zhang, Y.
6. Zhao, J.
7. Kim, D.-W.
8. Soo, R.A.
9. Kim, S.-W.
10. Pan, H.
11. Chen, Y.-M.
12. Chian, C.-F.
13. Liu, X.
14. Tan, D.S.W.
15. Bruns, R.
16. Straub, J.
17. Johne, A.
18. Scheele, J.
19. Park, K.
20. Yang, J.C.-H.
21. Liu, Z.
22. Chen, X.
23. Wang, M.
24. Yu, S.
25. Zhang, H.
26. Fang, J.
27. Li, W.
28. Yang, C.-H.
29. Chang, G.-C.
30. Hsia, T.-C.
31. Yang, C.-T.
32. Wang, C.-C.
33. Cho, B.C.
34. Lee, K.H.
35. Kim, Y.-C.
36. An, H.J.
37. Woo, I.S.
38. Cho, J.Y.
39. Shin, S.W.
40. Lee, J.-S.
41. Kim, J.-H.
42. Yoo, S.S.
43. Kato, T.
44. Shinagawa, N.
45. Tan, S.W.D.
46. Ngo, L.S.-M.
47. Ratnavelu, K.
48. Ahmad, A.R.
49. Liam, C.K.
50. de Marinis, F.
51. Tassone, P.
52. Molla, A.I.
53. Calles Blanco, A.
54. Lazaro Quintela, M.E.
55. Felip Font, E.
56. Dingemans, A.-M.
57. Bui, L.
58. Mostrar todos los/as autores/as +